Population Pharmacokinetics of Clesrovimab in Preterm and Full-Term Infants
This study, published in Clinical Pharmacology & Therapeutics (CPT), shows how population pharmacokinetic modeling supports…
CertaraFebruary 2, 2026
How Quantitative Systems Pharmacology Addresses Key Challenges in Alzheimer’s Drug Development
Quantitative Systems Pharmacology (QSP) helps address key challenges in Alzheimer’s disease drug development, including tau…
CertaraFebruary 2, 2026
Seeing is Understanding: Best Practices for Visualizing Nonclinical Study Data
SEND data visualization: best practices for visualizing nonclinical study data to reveal trends, spot outliers,…
CertaraFebruary 2, 2026
Opinion: To Accelerate Rare Disease Progress, Take a Sandbox Approach
Explore how a collaborative “sandbox” approach—combining flexible regulation, data modeling, and stakeholder engagement—can transform rare…
CertaraJanuary 30, 2026
Modeling Population PK with Power, Speed, and Ease-of-Use (Phoenix® NLME & Pirana®)
Discover population PK modeling made faster and easier with Phoenix NLME and Pirana in this…
CertaraJanuary 30, 2026
P21 Enterprise Expands Regulatory Validation Capabilities with Support for the Tobacco Implementation Guide v1.0
Pinnacle 21 supports TIG v1.0, the CDISC Tobacco Implementation Guide for FDA CTP, enabling automated…
CertaraJanuary 30, 2026
Certara to Report Fourth Quarter and Full Year 2025 Financial Results on February 26th, 2026
Radnor, Pa. — January 29, 2026 -- Certara, Inc. (Nasdaq: CERT), a global leader in…
CertaraJanuary 29, 2026
